Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience - Top-Institutions - MDSpire

Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience

  • By

  • Nicola Improda

  • Harshini Katugampola

  • Manuela Cerbone

  • Pratik Shah

  • Saji Alexander

  • Abigail Atterbury

  • Smail Hadj-Rabia

  • Catherine J Peters

  • Robert K Semple

  • Mehul Tulsidas Dattani

  • January 28, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH

    Bethesda, MD

    Key Differentiators

    • Endocrinology
    • Genetic Metabolic Disorders
    • Pediatric Endocrinology

  • #2

    Boston Children's Hospital, Harvard Medical School
    Boston Children's Hospital, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Pediatric Endocrinology
    • Genetic Metabolic Diseases

  • #3

    University of Cambridge, Metabolic Research Laboratories
    University of Cambridge, Metabolic Research Laboratories

    Cambridge, UK

    Key Differentiators

    • Endocrinology
    • Metabolic Genetics

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Rare Diseases

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Genetic Metabolic Disorders

Original Source(s)

Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience

  • by Nicola Improda, Harshini Katugampola, Manuela Cerbone, Pratik Shah, Saji Alexander, Abigail Atterbury, Smail Hadj-Rabia, Catherine J Peters, Robert K Semple, Mehul Tulsidas Dattani

  • January 28, 2026

Related Content

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives

AI system shows high accuracy for diabetic retinopathy screening

"AI could help reduce the burden on ophthalmology services by triaging large numbers of patients with diabetes and allowing specialists to focus on those who most urgently need care."